Sarcopenia in Patients With Idiopathic Pulmonary Fibrosis

NCT07178197 | Completed

• 1 other identifier: 2022/736
• Study Type: observational
• Target: 60
• Locations: 1 country
• Sites: 1

Brief Summary

Sarcopenia negatively affects the prognosis of chronic diseases. However, the importance of sarcopenia in patients with idiopathic pulmonary fibrosis (IPF) has been less emphasized. The aim of the study is to determine the prevalence of sarcopenia in patients with IPF and to evaluate the impact of sarcopenia on quality of life and disease progression. This study was designed as a descriptive cross-sectional. The study included patients diagnosed with IPF. Hand dynamometry and bioelectrical impedance analysis (BIA) were used to for diagnose of sarcopenia. Pulmonary function tests, maximal inspiratory pressure (MIP), and maximal expiratory pressure (MEP) measurements were examined. The 6-minute walk distance (6MWD) and 4-meter walking speed were recorded. The St. George Respiratory Questionnaire (SGRQ) was used to assess quality of life. All patients were evaluated for progressive disease.

Conditions

Idiopathic Pulmonary Fibrosis (IPF); Sarcopenia

Keywords

idiopathic pulmonary fibrosis; sarcopenia; skeletal muscle mass index; bioelectrical impedance analysis

Outcome Measures

Primary Outcomes (11)

• Hand Grip Strength

  Hand Grip Strength (kg)- Grip strength measurement using a hand dynamometer

  through study completion, an average of 1 year

• SMI (skeletal muscle mass index)

  SMI (skeletal muscle mass index) (kg/m2) - SMI measurement using the Bioelectrical Impedance Analysis (BIA) device

  through study completion, an average of 1 year

• Forced Expiratory Volume in 1 second (FEV1)

  Measurement of FEV1 for the assessment of pulmonary function

  through study completion, an average of 1 year

• Forced Vital Capacity (FVC)

  Measurement of FVC for the assessment of pulmonary function

  through study completion, an average of 1 year

• Diffusing Capacity of The Lungs for Carbon Monoxide (DLCO)

  Measurement of DLCO for the assessment of pulmonary function.

  through study completion, an average of 1 year

• Total Lung Capacity (TLC)

  Measurement of TLC for the assessment of pulmonary function.

  through study completion, an average of 1 year

• Respiratory Muscle Strength

  Measurement of maximal inspiratory pressure (MIP) and maximal expiratory pressure (MEP) for assessment of respiratory muscle strength

  through study completion, an average of 1 year

• Six Minute Walk Test (6MWT)

  Distance walked in six minutes (m)

  through study completion, an average of 1 year

• Gait speed

  4-meter walking speed (m/s)

  through study completion, an average of 1 year

• St. George's Respiratory Questionnaire (SGRQ)

  The questionnaire is designed to measure quality of life. It consists of symptom, activity, impact, and total scores. Each score ranges from 0 to 100. High scores indicate lower quality of life.

  through study completion, an average of 1 year

• Progressive Disease

  Examination of all participants from clinical, physiological, and radiological perspectives

  through study completion, an average of 1 year

Secondary Outcomes (1)

• Body Mass Index ( BMI)

  through study completion, an average of 1 year

Study Arms (1)

idiopathic pulmonary fibrosis (IPF)

The prevalence of sarcopenia was investigated in patients with IPF who met the inclusion and exclusion criteria. The relationship between sarcopenia and quality of life and disease progression in patients with IPF was evaluated.

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients included in the study were those diagnosed with IPF according to the ATS/ERS/JRS/ALAT 2022 guidelines and who applied to the Department of Pulmonary Diseases at Mersin University Faculty of Medicine.

You may qualify if:

• Being over 18 years of age
• Signing the informed consent form
• Having a diagnosis of IPF for at least one month

You may not qualify if:

• Pregnancy
• History of cancer within the last 5 years
• History of lung surgery
• History of neuromuscular disease
• Active pulmonary tuberculosis
• Active respiratory tract infection
• Inability to perform pulmonary function tests
• Presence of a pacemaker
• History of systemic steroid use within the past 3 months
• Inability to use a hand dynamometer

Sponsors & Collaborators

• Mersin University: lead

Study Sites (1)

Mersin University Faculty of Medicine

Mersin, Mersin, Turkey (Türkiye)

Location

MeSH Terms

Conditions

Idiopathic Pulmonary Fibrosis; Sarcopenia

Condition Hierarchy (Ancestors)

Pulmonary Fibrosis; Lung Diseases, Interstitial; Lung Diseases; Respiratory Tract Diseases; Muscular Atrophy; Neuromuscular Manifestations; Neurologic Manifestations; Nervous System Diseases; Atrophy; Pathological Conditions, Anatomical; Pathological Conditions, Signs and Symptoms; Signs and Symptoms

Study Design

• Study Type: observational
• Observational Model: OTHER
• Time Perspective: CROSS SECTIONAL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Prof. Dr.

Study Record Dates

• First Submitted: August 25, 2025
• First Posted: September 17, 2025
• Study Start: December 1, 2022
• Primary Completion: December 1, 2023
• Study Completion: December 31, 2023
• Last Updated: September 17, 2025

Record last verified: 2025-08

Data Sharing

• IPD Sharing: Will not share

Locations

TU (1)